表紙
市場調査レポート

トキソプラズマ症:パイプライン製品の分析

Toxoplasmosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 302504
出版日 ページ情報 英文 32 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
トキソプラズマ症:パイプライン製品の分析 Toxoplasmosis - Pipeline Review, H1 2016
出版日: 2016年06月08日 ページ情報: 英文 32 Pages
概要

トキソプラズマ症とは、トキソプラズマ寄生虫への感染により発症する疾患です。主な症状として、体中が痛んだり、リンパ節が腫れたり、頭痛・発熱・倦怠感が生じたりすることがあります。主なリスク要因には、HIV/AIDSや化学療法、免疫抑制剤などが含まれています。主な治療法として、抗マラリア薬や抗生物質などがあります。

当レポートでは、世界各国でのトキソプラズマ症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

トキソプラズマ症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

トキソプラズマ症:企業で開発中の治療薬

トキソプラズマ症:大学/機関で研究中の治療薬

トキソプラズマ症:パイプライン製品の概況

  • 初期段階の製品

トキソプラズマ症:企業で開発中の製品

トキソプラズマ症:大学/機関で研究中の製品

トキソプラズマ症の治療薬開発に従事している企業

Turing Pharmaceuticals AG

トキソプラズマ症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 分子タイプ別

薬剤プロファイル

トキソプラズマ症:休止中のプロジェクト

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8210IDB

Summary

Global Markets Direct's, 'Toxoplasmosis - Pipeline Review, H1 2016', provides an overview of the Toxoplasmosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Toxoplasmosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Toxoplasmosis
  • The report reviews pipeline therapeutics for Toxoplasmosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Toxoplasmosis therapeutics and enlists all their major and minor projects
  • The report assesses Toxoplasmosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Toxoplasmosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Toxoplasmosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toxoplasmosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Toxoplasmosis Overview
  • Therapeutics Development
    • Pipeline Products for Toxoplasmosis - Overview
    • Pipeline Products for Toxoplasmosis - Comparative Analysis
  • Toxoplasmosis - Therapeutics under Development by Companies
  • Toxoplasmosis - Therapeutics under Investigation by Universities/Institutes
  • Toxoplasmosis - Pipeline Products Glance
    • Early Stage Products
  • Toxoplasmosis - Products under Development by Companies
  • Toxoplasmosis - Products under Investigation by Universities/Institutes
  • Toxoplasmosis - Companies Involved in Therapeutics Development
    • Turing Pharmaceuticals AG
  • Toxoplasmosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Molecule Type
  • Drug Profiles
    • Monoclonal Antibody for Toxoplasmosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Polysaccharide for Oncology, Infectious Disease and Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Histone Deacetylase for Toxoplasmosis and Other Parasitic Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Toxoplasmosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • toxoplasmosis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • toxoplasmosis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • toxoplasmosis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRP-004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Toxoplasmosis - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Toxoplasmosis, H1 2016
  • Number of Products under Development for Toxoplasmosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Toxoplasmosis - Pipeline by Turing Pharmaceuticals AG , H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Toxoplasmosis - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Toxoplasmosis, H1 2016
  • Number of Products under Development for Toxoplasmosis - Comparative Analysis, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top